Launch One Acquisition's (LPAA) merger target Minovia Therapeutics said Monday it has been granted US Food and Drug Administration fast-track designation for its lead investigational compound MNV-201, which is intended as a treatment for Pearson Syndrome.
The company said the FDA also granted the drug candidate rare pediatric disease designation. The drug candidate is in phase 2 clinical trials for the treatment of the disease, the company said.
Launch One, a blank-check company, is expected to close its business combination with Minovia in late 2025, the company said.
Pearson Syndrome is a rare genetic disorder that leads to bone marrow failure, metabolic crises, and organ dysfunction.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。